首页> 外文OA文献 >Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion
【2h】

Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion

机译:血清IGF-1用于诊断创伤性脑损伤和运动相关震荡后生长激素缺乏的诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Growth hormone deficiency (GHD) is a potential consequence of traumatic brain injury (TBI), including sport-related concussion (SRC). GH stimulation testing is required for definitive diagnosis; however, this is resource intensive and can be associated with adverse symptoms or risks. Measurement of serum IGF-1 is more practical and accessible, and pituitary tumour patients with hypopituitarism and low serum IGF-1 have been shown to have a high probability of GHD. We aimed to evaluate IGF-1 measurement for diagnosing GHD in our local TBI population. Methods We conducted a retrospective chart review of patients evaluated for GHD at the TBI clinic and referred for GH stimulation testing with insulin tolerance test (ITT) or glucagon stimulation test (GST) since December 2013. We obtained demographics, TBI severity, IGF-1, data pertaining to pituitary function, and GH stimulation results. IGF-1 values were used to calculate z-scores per age and gender specific reference ranges. Receiver operator curve analysis was performed to evaluate diagnostic threshold of IGF-1 z-score for determining GHD by GST or ITT. Results Sixty four patient charts were reviewed. 48 patients had mild, six had moderate, eight had severe TBI, and two had non-traumatic brain injuries. 47 patients underwent ITT or GST. 27 were confirmed to have GHD (peak hGH < 5 μg/L). IGF-1 level was within the age and gender specific reference range for all patients with confirmed GHD following GH stimulation testing. Only one patient had a baseline IGF-1 level below the age and gender specific reference range; this patient had a normal response to GH stimulation testing. ROC analysis showed IGF-1 z-score AUC f, confirming lack of diagnostic utility. Conclusion Baseline IGF-1 is not a useful predictor of GHD in our local TBI population, and therefore has no value as a screening tool. TBI patients undergoing pituitary evaluation will require a dynamic test of GH reserve.
机译:摘要背景生长激素缺乏(GHD)是创伤性脑损伤(TBI)的潜在后果,包括与运动相关的脑震荡(SRC)。最终诊断需要GH刺激测试;然而,这是资源密集型,可以与不利症状或风险相关。血清IGF-1的测量更实用可用,并且已显示低血清IGF-1的垂体肿瘤患者具有高概率的GHD。我们旨在评估IGF-1在当地TBI人口中诊断GHD的测量。方法对TBI诊所的GHD评估的患者进行了回顾性图表综述,并提到了自2013年12月以来的胰岛素耐受试验(ITT)或胰高血糖素刺激测试(GST)的GH刺激测试。我们获得了人口统计学,TBI严重程度IGF-1 ,与垂体功能有关的数据,以及GH刺激结果。 IGF-1用于计算每个年龄和性别特异性参考范围的Z分数。进行接收器操作符曲线分析以评估IGF-1 Z分数的诊断阈值,以通过GST或ITT确定GHD。结果综述了六十四名患者图表。 48例患者患有温和,六个中度,八个患有严重的TBI,两次有两种具有非创伤性脑损伤。 47名患者接受ITT或GST。确认27具有GHD(峰HGH <5μg/ L)。 IGF-1级别在GH刺激测试之后确诊的所有患者的年龄和性别特异性参考范围内。只有一名患者在年龄和性别特异性参考范围以下都有基线IGF-1水平;该患者对GH刺激测试具有正常响应。 ROC分析显示IGF-1 Z-GRASE AUC F,证实缺乏诊断效用。结论基线IGF-1不是本地TBI人口中GHD的有用预测因子,因此没有作为筛选工具的价值。接受垂体评估的TBI患者将需要对GH储备的动态测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号